Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave by Read, Jonathan M et al.
 
 
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 




Submissions should be 
made via our electronic 
submission system at 
http://ees.elsevier.com/
thelancet/
www.thelancet.com   Vol 398   September 18, 2021 1037
Hospital-acquired 
SARS-CoV-2 infection in 
the UK’s first COVID-19 
pandemic wave
Prevention of hospital-acquired 
infections is a critical aspect of 
clinical management of COVID-19 
as hospital-acquired infections have 
been a common feature of previous 
novel coronavirus outbreaks.1 The 
number of COVID-19 patients in UK 
hospitals reached high levels during 
the first pandemic wave of 2020, and 
higher levels still in the subsequent 
winter wave. We assessed the mag-
nitude of nosocomial COVID-19 in 
acute and long-term National Health 
Service (NHS) hospital facilities in 
the UK during the first pandemic 
wave.
We examined records of COVID-19 
patients in UK hospitals enrolled 
in the International Severe Acute 
Respiratory and emerging Infections 
Consortium (ISARIC) WHO Clinical 
Characterisation Protocol  UK 
(CCP-UK) study, with symptom onset 
before Aug 1, 2020.2,3 We identified 
patients as having hospital-acquired 
infections using a combination of 
their admission date and symptom 
onset date, and estimates of their 
infection date based on the known 
incubation period distribution 
of SARS-CoV-2.4 To incorporate 
uncertainty in individual patient’s 
incubation periods, we imputed 
infection dates for patients and 
identified those admitted before 
infection as having hospital-acquired 
infections. Multiple imputation 
was used to generate estimates and 
CIs (appendix). We estimate that 
11·3% (95% CI 11·1–11·6) of patients 
with COVID-19 in 314 UK hospitals 
became infected after hospital admis-
sion. This proportion increased to 
at least 15·8% (17·6%; 15·8–19·6) 
of patients with COVID-19 by the 
middle of May, 2020, long after 
the peak of admissions. Using an 
extremely conservative threshold 
of symptom onset at least 14 days 
after admission to identify hospital-
acquired infections, we estimate 
that 6·8% (95% CI 6·7–7·0) of 
all patients with COVID-19 had 
nosocomial infections, with a peak 
of 8·2% (7·0–9·6) of patients having 
nosocomial infections in mid-May.
There was marked heterogeneity 
in hospital-acquired infection 
proportion between hospital trusts 
and by the nature of care they provide 
(figure). Hospitals providing acute 
and general care had lower hospital-
acquired infection proportions (9·7%; 
95% CI 9·4–9·9) than residential 
community care hospitals (61·9%; 
56·4–68·0) and mental health 
hospitals (67·5%; 60·1–75·8), 
reflecting outbreaks seen in care 
homes. The reasons for the variation 
between hospitals providing the 
same type of care require urgent 
investigation to identify and promote 
best infection control practice for 
future treatment of COVID-19 
patients.
As ISARIC WHO CCP-UK data 
are a subset of all admissions 
(approximately two-thirds sample 
in the period of observation), we 
estimated the number of hospital-
acquired infections by hospital trust, 
accounting for the participation rate 
of each hospital trust in comparison 
to NHS Digital Secondary Uses 
Service data. We estimated that of 
82 624 patients admitted before 
Aug 1, 2020, 5699–11 862 patients 
were infected during their hospital 
stay. Underestimation is probable 
since ISARIC4C data cannot identify 
patients infected during admission 
but discharged before manifesting 
symptoms, or patients infected during 
another health-care visit before 
admission.
Limited access to testing early in 
the outbreak, false negative results 
for nasopharyngeal swabs in early 
stages of disease, and presentation 
with gastrointestinal symptoms 
may have led to some patients with 
COVID-19 being misclassified and 
Figure: Estimated proportion of COVID-19 patients with hospital-acquired infection based on 72 157 patients with complete admission and symptom onset 
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Neutralising antibodies 
after COVID-19 
vaccination in UK 
haemodialysis patients
Vaccination against COVID-19 induces 
highly protective immune responses 
in most people. As some countries 
switch from suppression to acceptance 
of transmission of SARS-CoV-2 within 
a largely vaccinated adult population, 
vulnerable patient groups that have not 
mounted adequate immune responses 
to vaccination might experience 
significant morbidity and mortality. 
There is an urgent need to identify such 
patient groups and to optimise medical 
advice and vaccination strategies for 
them.
In-centre haemodialysis patients 
are a particularly vulnerable group. 
During the first wave of the COVID-19 
pan demic (March 1 to Aug 30, 2020), 
4666 cases and 1373 deaths in in-
centre haemodialysis patients were 
reported to the UK’s Renal Registry,1 
a case fatality rate of 29%. In the UK, 
although these patients were treated 
as clinically extremely vulnerable, they 
were unable to fully shield because of 
mandatory life-sustaining attendance 
at haemodialysis (typically three 4-h 
sessions per week), and instances of in-
unit transmission have been shown by 
sequencing viral isolates.2
Vaccine responses are substantially 
attenuated in patients who need 
haemodialysis. For example, the 
subunit hepatitis B vaccine had to be 
re-formulated for this patient group to 
deliver a higher antigenic dose.3 There 
is uncertainty whether an mRNA or an 
adenoviral-vectored COVID-19 vaccine 
could provide clinical protection in 
this popula tion or how long that 
protection lasts given the known 
waning of SARS-CoV-2 antibodies 
after natural infection.4
In the UK, most in-centre haemo-
dialysis patients were vaccinated by 
their dialysis care team as part of the 
Joint Committee on Vaccination and 
Immunisation (JCVI) priority group 4,3 
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placed in non-COVID-19 areas with 
different infection prevention control 
processes.3 Enteric features, and the 
ability of SARS-CoV-2 to persist on 
surfaces, raise the possibility of faecal-
oral transmission in care settings 
under severe pressure, although the 
role of this transmission route is 
uncertain.5
As SARS-CoV-2 is likely to persist 
as an endemic or seasonal virus in 
coming years, it is critical to use the 
lessons learned so far in the pandemic 
to minimise the burden of hospital-
acquired infections, and to consider 
new approaches to reduce the 
burden further. Surveillance afforded 
by this study has helped to rapidly 
identify changes in hospital-acquired 
infection incidence in different 
health-care settings. Unlike at the 
beginning of the pandemic, there are 
opportunities to pre-empt hospital-
acquired infections and break chains of 
transmission through regular patient, 
resident, and staff testing including 
point-of-care diagnostics, as recently 
introduced for NHS staff, coupled with 
robust hospital infection prevention 
and control policies that include 
staff vaccination, environmental 
disinfection, and appropriate isolation, 
all supported by sentinel monitoring 
systems.
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